Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 4/20 | 0.35 |
| ▸ | KIT | P10721 | 2/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.34 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | CLK1 | P49759 | 1/20 | 0.33 |
| ▸ | CLK2 | P49760 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.32 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2823038 | 0.81 | KCNH2 (0.43) | CSF1RKCNH2MAP4K4KITPDE10A | |
| SCHEMBL14361196 | 0.80 | SRC (0.39) | CSF1RKCNH2MAP4K4SRCPDE10A | |
| SCHEMBL3278716 | 0.79 | SRC (0.39) | CSF1RKCNH2MAP4K4SRCEGFR | |
| SCHEMBL22013370 | 0.79 | KCNH2 (0.38) | CSF1RKCNH2MAP4K4SRCKIT | |
| SCHEMBL2819930 | 0.79 | CSF1R (0.40) | CSF1RKCNH2MAP4K4SRCKIT | |
| SCHEMBL592871 | 0.79 | KCNH2 (0.38) | KCNH2 | |
| SCHEMBL3272172 | 0.79 | KCNH2 (0.35) | KCNH2MAP4K4PDE10AEGFR | |
| SCHEMBL5263274 | 0.73 | CSF1R (0.34) | CSF1RKCNH2KITPDE10A | |
| SCHEMBL14993933 | 0.73 | CSF1R (0.33) | CSF1RKCNH2MAP4K4KIT | |
| SCHEMBL3273397 | 0.73 | MAP2K1 (0.52) | SRCHPGDSEGFRRAF1MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691850-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| US-7691850-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| US-7691850-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| EP-1796466-A4 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2009-09-02 | — | — | EP | disclosed |
| EP-1784410-A4 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2009-07-15 | — | — | EP | disclosed |
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | SMITHKLINE BEECHAM CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | SMITHKLINE BEECHAM CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | SMITHKLINE BEECHAM CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070254872-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | US | disclosed |
| US-20070254872-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | US | disclosed |
| US-20070161627-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2007-07-12 | — | — | US | disclosed |
| US-20070161627-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2007-07-12 | — | — | US | disclosed |
| EP-1796466-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-06-20 | — | — | EP | disclosed |
| EP-1784410-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-05-16 | — | — | EP | disclosed |
| EP-1773831-A1 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-04-18 | — | — | EP | disclosed |
| WO-2007016610-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007016610-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
| WO-2006020561-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006014580-A1 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-02-09 | — | — | WO | disclosed |
| WO-2006002047-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | NPM1, TOP1, HMGB1 | CSF1R 2839/4885KCNH2 3440/4885MAP4K4 754/4885 |
| US-20070161627-A1 | Antibacterial agents | NQO2, NQO1, NDUFV2 | CSF1R 2626/4885KCNH2 2586/4885MAP4K4 813/4885 |
| US-20070254872-A1 | Antibacterial Agents | NQO2, NQO1, NDUFV2 | CSF1R 2626/4885KCNH2 2586/4885MAP4K4 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.